Last reviewed · How we verify
RT plus Nimotuzumab
Nimotuzumab is a monoclonal antibody that blocks epidermal growth factor receptor (EGFR) signaling, combined with radiotherapy (RT) to enhance tumor cell death in cancer treatment.
Nimotuzumab is a monoclonal antibody that blocks epidermal growth factor receptor (EGFR) signaling, combined with radiotherapy (RT) to enhance tumor cell death in cancer treatment. Used for Head and neck cancer (in combination with radiotherapy), Nasopharyngeal carcinoma (in combination with radiotherapy).
At a glance
| Generic name | RT plus Nimotuzumab |
|---|---|
| Sponsor | Sun Yat-sen University |
| Drug class | EGFR inhibitor monoclonal antibody |
| Target | EGFR (Epidermal Growth Factor Receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Nimotuzumab binds to EGFR on cancer cells, preventing ligand-induced activation and downstream proliferation signals. When combined with radiotherapy, it enhances radiosensitivity and reduces tumor cell survival. This combination approach targets both the growth factor signaling pathway and DNA damage response mechanisms.
Approved indications
- Head and neck cancer (in combination with radiotherapy)
- Nasopharyngeal carcinoma (in combination with radiotherapy)
Common side effects
- Acneiform rash
- Radiation dermatitis
- Mucositis
- Fatigue
- Dysphagia
Key clinical trials
- Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma (PHASE3)
- Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer (PHASE3)
- Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses (PHASE2)
- Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer (PHASE2)
- Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma (PHASE3)
- Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer (PHASE2)
- Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma (PHASE2)
- A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |